HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained an $11 price target.
August 14, 2023 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Y-mAbs Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $11.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Y-mAbs Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100